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Abstract  
The efficacy of temozolomide (TMZ) treatment for cancers is currently limited by 
inherent or the development of resistance, particularly, but not exclusively, due to the 
expression of the DNA repair enzyme O6-methylguanine-DNA methyltransferase 
(MGMT) in a significant proportion of tumors. We have found that TMZ analog C8-
methyl imidazole tetrazine (PMX 465) displayed good anticancer activity against the 
colorectal carcinoma HCT116 cells which are MGMT-overexpressing and mismatch 
repair (MMR)-deficient. In this study, we found that PMX 465 could downregulate the 
expression of MGMT in HCT116 cells at the protein and mRNA levels. We found that 
PMX 465 could reduce MGMT expression by increasing the binding of wild-type p53 
to the MGMT promoter and reducing the binding of Sp1 to the MGMT promoter. This 
article is protected by copyright. All rights reserved 
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Introduction 
O6-methylguanine-DNA methyltransferase (MGMT), a ubiquitous DNA repair 
protein, reverses mutagenic and cytotoxic effects of O6-alkylguanine in DNA induced 
by alkylating agents. Each single alkyl group removed from O6-alkylguanine is 
transferred to a cysteine residue within the active site of MGMT in a stoichiometric 
second-order reaction, implying the inactivation of one MGMT enzyme molecule for 
each alkyl group removed from alkylguanine, a process termed suicide 
inhibition(Cabrini et al., 2015; Zhang et al., 2012). Consequently, the effciency of O6-
alkylguanine repair is limited by the number of molecules of MGMT enzyme available, 
also considering that the dealkylating function of MGMT does not possess redundant 
pathways. The high expression of MGMT in tumor cells imparts resistance to TMZ 
chemotherapy(Cabrini et al., 2015; Ramirez et al., 2013). Therefore, combinations of 
MGMT inhibitors such as O6-BG with TMZ to treat cells that overexpress MGMT has 
been attempted(Wedge et al., 1996). However, myelosuppression limits the use of 
MGMT inhibitors and alkylating agent combination chemotherapy(Warren et al., 2012). 
In addition, resveratrol and ursolic acid (UA) have been reported to reverse TMZ 
resistance by downregulation of MGMT in glioblastoma cells. Moreover, experimental 
results in a mouse xenograft model showed that the combination treatment of 
resveratrol/UA and TMZ reduced tumor volumes by depleting MGMT(Lin et al., 2012; 
Zhu et al., 2016). Therefore, they might be candidate agents for patients with MGMT-
overexpressing tumors. 
MGMT expression is regulated by a variety of factors, such as promoter 
methylation and transcription factors(Cabrini et al., 2015). DNA methylation can 
repress gene transcription either by interfering with the function of transcription factors 
by cytosine methylation of the recognition sites or by recruiting methyl CpG binding 
domain (MBD) containing family proteins. Some of MBD proteins have been shown 
to be able to recruit histone deacetylase (HDAC) directly or through adjuvant repressors. 
And HDAC can cause histone to be deacetylated, resulting in chromosome compression, 
isolation of transcription factors and inhibition of transcription(Danam et al., 2005). 
In addition, different transcription factors have been found to activate transcription 
of the MGMT gene, including Sp1, NF-κB, CEBP and AP-1(Cabrini et al., 2015). 
Among them, specificity protein (Sp) transcription factors play a critical role in 
embryonic and early postnatal development. The Sp family members are zinc finger 
proteins; with the exception of Sp2, most of Sp family members could bind GC/GT 
sequences that are widely distributed in the human genome(Safe et al., 2014). The study 
found that Sp1, Sp3 and Sp4 were highly expressed in many tumor cells, and they 
played a part in tumor cell proliferation, survival, inflammation, angiogenesis and 
infiltration by regulating cancer-causing factors. In addition, Sp1 is a negative 
prognostic factor for some tumor treatments (Safe et al., 2014; Vizcaino et al., 2015). 
The MGMT promoter contains six putative Sp1-binding sequences, and Sp1 binding 
could promote MGMT expression(Bocangel et al., 2009). 
The transcription factor p53 has a wide range of functions in cell cycle arrest, DNA 
repair and apoptosis through transactivation of specific genes in response to DNA 
damage and other cellular stress signals(Bocangel et al., 2009). In spite of the lack of 
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typical p53-binding sites in the MGMT promoter, several studies have found that the 
tumor suppressor p53 impacts MGMT expression(Bobustuc et al., 2015; Bocangel et 
al., 2009; Natsume et al., 2005). In addition, it has been reported that p53 protein 
directly interacts with the MGMT promoter and downregulates MGMT 
transcription(Natsume et al., 2005). 
The TMZ derivative C8-methyl imidazole tetrazine, 3-methyl-8-(1-
methylimidazol-2-yl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (PMX 465 or 465, Fig 
1), is able to induce apoptosis in MGMT-overexpressing and MMR-deficient HCT116 
colon cancer cells(Yang et al., 2017). In this study, we found that PMX 465 could 
downregulate the expression of MGMT in HCT116 cells at the mRNA and protein 
levels. The mechanism of MGMT downregulation by PMX 465 was likely related to 
modulation of MGMT promoter binding with wild-type p53 and Sp1 in HCT116 cells. 
 
Materials and Methods 
   Cell lines and reagents 
   HCT116 (hMLH1-) colorectal carcinoma cells , H1299 (p53-/-) non-small cell lung 
carcinoma cells and MCF-7 breast carcinoma cells were obtained from the American 
Type Culture Collection (ATCC) and grown in RPMI 1640 medium supplemented with 
10% fetal bovine serum (FBS). T98G glioblastoma cells (sourced from the ATCC) were 
maintained in DMEM medium supplemented with 10% FBS. Cells were all incubated 
in a humidified atmosphere of 95 % air and 5 % CO2 at 37 °C. TMZ was provided by 
Schering-Plough Research Institute (Kenilworth, N.J., USA). Novel analog PMX 465 
was synthesized at Pharminox Ltd, BioCity, Nottingham, UK. Compounds were 
prepared as 100 mM stock solutions in dimethyl sulfoxide (DMSO) and stored at –
20 °C. Reagents, unless specified otherwise, originated from Sigma-Aldrich Ltd. 
 
Western Blot Analysis 
Cells were lysed in RIPA lysis buffer (25 mM Tris HCl (pH 7.5), 2.5 mM EDTA, 
20 mM NaF, 1 mM Na3VO4, 100 mM NaCl, 20 mM sodium glycerophosphate, 10 mM 
sodium pyrophosphate, 0.5% triton X-100) supplemented with a protease inhibitor 
cocktail (Roche). Cellular proteins (30 μg) were separated by SDS-PAGE, and electro-
transferred onto PVDF membranes. Membranes were blocked in Tris-buffered saline 
(TBS) containing 5% milk and 0.1% Tween-20 at room temperature. All primary 
antibodies (tubulin, p53, p65 and p-p65 from Cell Signaling; Sp1 and MGMT from 
Abcam; GAPDH form Millipore) were incubated overnight at 4 °C; membranes were 
washed at room temperature before incubation with a secondary antibody (GE) 
conjugated with horseradish peroxidase for 1 h. Detection was performed with Super 
Signal Chemiluminescent reagent according to the manufacturer’s protocol 
(Tanon ,China). 
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Real-time PCR 
Total RNA was prepared using a total RNA kit (AXYGEN). cDNA was prepared 
from 1 μg of total RNA using reverse transcription kit (Promega GoScript). The 
reaction mixture included 1 μL of cDNA, 2 μL 10 μM forward and reverse primers mix 
(Songgong), 2 μL pure water and 5 μL SYBR green (SYBR Green Master Mix, 
RCHIO), in a total volume of 10 μL. Gene amplification was carried out using the 
GeneAmp 7000 Sequence Detection System (Applied Biosystems). Amplification 
included one stage of 10 min at 95 °C, followed by 40 cycles of a two-step loop: 15 s 
at 95 °C and 1 min at 60 °C. The gene expression results were normalized to the 
GAPDH gene.  
All experiments were repeated three to five times in triplicate and data are 
presented as means ± SD. The primers used for real-time PCR were MGMT, 5’- 
ACCGTTTGCGACTTGGTACTT-3’ (forward) and 5’- GGAGCTTTATTTCGTGCA 
GACC-3' (reverse)；GAPDH, 5'-TGCACCACCAACTGCTTAG -3’ (forward) and 5'- 
GGCATGGACTGTGGTCAT -3’ (reverse). 
 
Chromatin immunoprecipitation assay (ChIP) 
The chromatin immunoprecipitation assay was performed according to the 
manufacturer`s (Millipore) protocol. The specific antibodies used for 
immunoprecipitation were the anti-p53 antibody and accordant rabbit secondary 
antibody. After protein-DNA cross-links in the immunoprecipitates were reversed, the 
purified DNA was analyzed by PCR (35 cycles; 45 seconds at 95 °C, 45 seconds at 
55 °C, 60 seconds at 72 °C) with primers that detect the MGMT promoter sequence 
[5’-GCTCCAGGGAAGAGTGTCCTCTGC-TCCCT-3’ (forward) and 5’-
GGCCTGTG GTGGGCGATGCCGTCCAG-3’(reverse)]. The PCR products were 
visualized on an ethidium bromide gel. 
 
Transfection assay  
HCT116 cells were cotransfected with 1.5 μg of each negative control plasmid 
(NC) and three p53 shRNA plasmids (678, 968 and 1043) using LipofectAMINE 2000 
(Gibco Life Technologies), according to the manufacturer’s instructions. These 
plasmids were a gift from Dr. Wei-Lin Jin (Shanghai Jiao Tong University). 
 
Electrophoretic mobility shift analysis (EMSA)  
EMSA was performed as described(Bocangel et al., 2009) with some 
modifications. The 5’ biotin-labeled’ oligo 5'-GCCCCGGCCCCGCCCCCGCGCG-3’ 
(sense, containing a Sp1-binding site present in the MGMT promoter) was annealed 
with appropriate complementary strands to generate duplex oligo. Then, this 
experiment was performed according to the protocol of the EMSA Kit (Thermo). 
Specifically, the DNA (10 fmol) was incubated with extracts (10 μg) isolated from 
HCT116 cells for 20 min at 25 ˚C in 20 μL buffer containing 1X Binding Buffer, 5 mM 
MgCl2, 0.05% NP-40, 2.5% glycerol and 50 ng/μL poly (dI-dC). These mixtures were 
separated by nondenaturing 6% polyacrylamide gels in Tris-borate buffer, and electro-
transferred onto cellulose membrane. Then the membrane and mixture were crosslinked 
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at 120 mJ/cm2 using 254 nm UV-light bulbs for 60 s. Finally, biotin-labeled DNA was 
detected by Chemiluminescence according to the EMSA Kit’s protocol (Thermo). 
 
Results 
Analog PMX 465 reduced the expression of MGMT in HCT116 cells 
High expression of MGMT is a major clinical reason for the resistance of tumor 
cells to TMZ(Cabrini et al., 2015; Ramirez et al., 2013). A previous study identified 
that TMZ analog C8-methyl imidazole tetrazine (PMX 465) displayed good anticancer 
activity against the colorectal carcinoma HCT116 cells with high MGMT expression 
levels and MMR deficiency(Zhikuan Yang et al., 2017). We treated HCT116 cells with 
TMZ (50 μM), PMX 465 (50 μM) and O6-BG (10 μM) for 48 h, and lysates from 
compound-treated cells were subjected to Western blot analysis for MGMT protein 
detection. Compared with control and TMZ treatment groups, we found that PMX 465 
and O6-BG (MGMT inhibitor) could reduce the expression of MGMT (Fig 2A). 
Subsequently, HCT116 cells were exposed to 20, 35 and 50 μM PMX 465 for 48 h. As 
shown in Fig 2B, PMX 465 down-regulated MGMT in a concentration-dependent 
manner, and PMX 465 concentrations ≥35 μM PMX 465 could decrease the expression 
of MGMT. Next, HCT116 cells were treated with TMZ (50 μM), PMX 465 (50 μM) 
and O6-BG (10 μM) for 12, 24 and 48 h. The results showed that PMX 465 reduced 
MGMT expression in a time-dependent manner (Fig 2C). Next, mRNA levels of 
MGMT were investigated in HCT116 cells following exposure to TMZ (50 μM), PMX 
465 (50 μM) and O6-BG (10 μM) for 24 and 48 h. As shown in Fig 2D, PMX 465 could 
decrease MGMT mRNA levels at 24 and 48 h significantly, while TMZ and O6-BG 
treatments had no effect on MGMT mRNA expression levels. These data indicate that 
TMZ analog PMX 465 could down-regulate the expression of MGMT in HCT116 cells 
at both protein and mRNA levels.  
PMX 465 downregulated MGMT expression via protein p53 
It has been found that transcription factor p53 binds directly to the MGMT 
promoter and inhibits the expression of MGMT(Natsume et al., 2005). Western blotting 
analysis was performed to monitor p53 expression after TMZ (50 μM), PMX 465 (50 
μM) and O6-BG (10 μM) treatment for 48 h. We found that only PMX 465 (50 μM) 
treatment increased p53 protein expression in HCT116 cells (Fig 3A). HCT116 cells 
were then treated with TMZ (50 μM) and PMX 465 (20, 35 and 50 μM) for 48 h. As 
shown in Fig 3B, PMX 465 upregulated p53 expression in a concentration-dependent 
manner. To further investigate whether PMX 465 disrupts p53 protein interaction with 
the MGMT promoter and downregulates transcription of MGMT, we carried out 
chromatin immunoprecipitation (ChIP) assays. Increased binding of p53 to the MGMT 
promoter was observed after treatment of HCT116 cells with 50 μM PMX 465 for 48 
h (Fig 3C). Subsequently, p53 expression in HCT116 cells was knocked down, to 
further investigate whether PMX 465 regulates MGMT expression via p53. As shown 
in Fig 3D, two p53 shRNA plasmids (968 and 1043) specifically knocked down the p53 
protein. It was found that knockdown of p53 by shRNA increased MGMT expression 
in HCT116 cells exposed to 50 μM PMX 465 for 48 h (Fig 3E). These results suggest 
that PMX 465 down-regulates MGMT expression in HCT116 cells via p53 protein. 
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Effect of PMX 465 on MGMT expression in cells possessing different p53 
status 
In order to confirm that PMX 465 caused MGMT downregulation via a 
mechanism involving p53, MCF-7 breast carcinoma cells (wt p53 and MGMT 
overexpression) were treated with 50 μM TMZ or PMX 465 for 48 h. Compared with 
control and TMZ, PMX 465 augmented p53 expression accompanied by MGMT 
protein reduction (Fig 4A). We further studied the influence of PMX 465 on MGMT 
expression in cell lines expressing mutant (mt) or no p53. H1299 (p53-/-) NSCLC (non-
small cell lung carcinoma) cells and T98G (mt p53) GBM (glioblastoma) cells were 
exposed to TMZ (50 μM) or PMX 465 (50 μM) for 48 h. We observed that PMX 465 
had no effect on MGMT expression in these cells (Fig 4B and C). These data suggest 
that MGMT downregulation by PMX 465 was involved with wild type p53. 
DNA damaging compounds decreased MGMT expression  
P53 serves as a common transcription factor, responding to DNA damage induced 
by chemotherapeutic agents(Mirzayans et al., 2017). Therefore, we investigated 
whether other DNA damaging drugs regulate MGMT expression by inducing increased 
expression of p53. HCT116 cells were treated with doxorubicin (DOX), (0.25, 0.5 and 
1 μg/mL) and cisplatin (DDP) (2.5, 5 and 10 μM) for 48 h; it was found that 1 μg/mL 
DOX, 5 and 10 μM DDP can upregulate p53 while decreasing MGMT protein 
expression (Fig 5A and B). These results indicate that DNA damaging 
chemotherapeutic compounds may down-regulate MGMT expression in HCT116 cells 
via a mechanism involving p53. 
PMX 465 reduced MGMT expression by transcription factor Sp1 
It has been reported that the MGMT promoter contains multiple Sp1 binding sites, 
and transcription factor Sp1 binding could promote MGMT expression(Bocangel et al., 
2009). Western blotting analysis was performed to detect Sp1 expression in HCT116 
cells after treatment (48 h) with TMZ (50 μM), PMX 465 (50 μM) and O6-BG (10 μM). 
We found that only PMX 465 could decrease Sp1 protein expression (Fig 6A). HCT116 
cells were then exposed to TMZ (50 μM) and PMX 465 (20, 35 and 50 μM) for 48 h. 
As shown in Fig 6B, PMX 465 reduced Sp1 protein expression in concentration-
dependently. To test whether PMX 465 interferes with Sp1 binding to its consensus site 
in the MGMT promoter, we performed EMSA using a consensus Sp1-binding sequence 
(Fig 6C) present in the MGMT promoter. Significant reduction in the binding of the 
nuclear extract was observed in HCT116 cells treated with 50 μM PMX 465 for 48 h 
(Fig 6D; compare lanes 3 and 4). Moreover, the signal shift observed in lane 3 could be 
prevented by competition from excess non-labeled DNA (Figure 6D; lane 2). These 
data suggest that MGMT down-regulation by PMX 465 in HCT116 cells is regulated 
by transcription factor Sp1. 
 
Discussion 
MGMT is critical for direct repair of O6-methylguanine DNA adducts, and its high 
expression confers TMZ resistance(Cabrini et al., 2015; Zhang et al., 2012). Therefore, 
inhibition of MGMT with several O6-methylguanine derivatives and other compounds 
has been explored and shown to enhance TMZ-induced cytotoxicity in tumor cells(Fan 
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et al., 2013). For example, O6-BG is an O6-methylguanine analog that binds to MGMT 
directly, inducing degradation of MGMT(Wedge et al., 1996). However, 
myelosuppression manifesting as neutropenia, leukopenia and thrombocytopenia was 
mainly responsible for the limitation of O6-BG and alkylating agent combination 
chemotherapy(Warren et al., 2012). In addition, other drugs such as resveratrol and 
ursolic acid have been reported to attenuate TMZ resistance by downregulation of 
MGMT in glioblastoma cells and the combination of these compounds with TMZ 
displayed good anticancer activity in GBM cells which over-express MGMT(Lin et al., 
2012; Zhu et al., 2016).  
Our earlier studies showed that TMZ analog C8-methyl imidazole tetrazine (PMX 
465) (Fig 1) could induce DNA damage and apoptosis in MGMT-overexpressing, 
MMR-deficient HCT116 colon cancer cells (Zhikuan Yang et al., 2017). In this study, 
we found that PMX 465 could deplete MGMT expression in HCT116 cells at the 
protein and mRNA levels, while O6-BG only decreased MGMT protein (Fig 2A and 
D). These results indicate that PMX 465 might not act in the same way as O6-BG which 
depletes MGMT as its substrate. It is known that MGMT expression is regulated by a 
number of processes, such as MGMT promoter methylation, histone acetylation and 
transcription factor activity(Cabrini et al., 2015). 
Studies have shown that p53 is associated with the expression of MGMT, and it 
has been reported that p53 can bind directly to the MGMT promoter to inhibit its 
expression(Natsume et al., 2005). Initially, we found that the expression of p53 was 
upregulated and accompanied MGMT expression reduction in HCT116 cells treated 
with 50 μM PMX 465 for 48 h (Fig 3A). The reduction of MGMT by PMX 465 was 
probably related to increasing binding of protein p53 to the MGMT promoter as 
evidenced by ChIP and confirmed by down-regulating p53 expression with shRNA p53 
plasmid (Fig 3C and E). In order to confirm that wt p53 is essential to MGMT down-
regulation, MCF-7 breast carcinoma cells (wt p53 and MGMT+) were treated with 
PMX 465 (50 μM) for 48 h. We found that PMX 465 could increase p53 expression 
and reduce MGMT protein in MCF-7 cells (Fig 4A). In addition, to further study the 
effect of PMX 465 on MGMT expression, cells exhibiting null and mutant p53 
backgrounds, H1299 (p53-/-) NSCLC cells and T98G (mt p53) GBM cells were treated 
with PMX 465 (50 μM) for 48 h; no MGMT reduction was observed in these cells (Fig 
4B and C). Therefore, wt p53 appears indispensible for down-regulation of MGMT by 
PMX 465. P53 serves as a common transcription factor, and responds to DNA damage 
induced by ionizing radiation, UV light and chemotherapeutic agents(Bocangel et al., 
2009; Mirzayans et al., 2017). Therefore, we speculated whether other DNA damaging 
agents might regulate MGMT expression via increased p53 expression. HCT116 cells 
were exposed to DOX (0.25, 0.5 and 1 μg/mL) or DDP (2.5, 5 and 10 μM) for 48 h; 
DOX (1 μg/mL) and DDP (5 and 10 μM) were able to reduce MGMT protein expression 
by up-regulating p53 expression (Fig 5A and B). These results may imply that some 
DNA damaging compounds may down-regulate MGMT expression via protein p53. 
Sp family members sp1, sp3 and sp4 are highly expressed in many tumors and 
play a critical role in embryonic and early postnatal development. There is evidence 
that Sp1 expression decreases with age in humans and is a negative prognostic factor 
 
 
  
 A
cc
ep
te
d
  A
rt
ic
le
 
 
 
 
 
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved 
 
for survival of gastric, pancreatic cancer and glioma patients(Safe et al., 2014; Vizcaino 
et al., 2015). In addition, previous studies have shown that several pro-oncogenic Sp-
regulated genes are important for cell growth, survival, angiogenesis and inflammation. 
The MGMT promoter contains six putative Sp1-binding sites, and Sp1 can bind directly 
to the promoter to promote MGMT expression(Bocangel et al., 2009). We found that 
PMX 465 reduces MGMT expression via interference with Sp1. Firstly, PMX 465 is 
able to reduce Sp1 protein levels in HCT116 cells (Fig 6A). Moreover, as evidenced 
EMSA experiments, binding between Sp1 and the MGMT promoter was reduced 
following treatment of cells with 50 μM PMX 465 for 48 h (Fig 6D). Sp1 protein could 
be downregulated by caspases, activation of proteasomes or drug-induced ROS 
generation(Safe et al., 2014; Vizcaino et al., 2015). However, the mechanism by which 
PMX 465 decreases Sp1 expression remains to be elucidated. 
Notably, nuclear factor-κB (NF-κB) is also involved in transcriptional regulation 
of MGMT through direct interaction with two putative NF-κB binding sequences 
within the MGMT promoter region(Lavon et al., 2007). It has been reported that 
resveratrol, fluoxetine and bortezomib attenuated MGMT expression by disrupting NF-
κB signaling(Lin et al., 2012; Song et al., 2015; Vlachostergios et al., 2013). Our results 
showed that PMX 465 treatment did not change p65（the subunit of NF-κB）and active 
P-p65 protein levels (Fig S1A). We performed EMSA using a consensus NF-κB binding 
sequence present in the MGMT promoter and found that the binding did not change in 
HCT116 cells treated with 50 μM PMX 465 for 48 h (Fig S1B).  
In addition to transcription factor activation, promoter methylation levels and 
chromatin remodeling can also affect MGMT expression(Nakagawachi et al., 2003). 
We also investigated the effect of PMX 465 on MGMT promoter methylation in 
HCT116 cells using bisulfate sequencing PCR (BSP). The promoter sequence contains 
the usual MSP detection sites. The results showed that PMX 465 did not alter 
methylation in HCT116 MGMT promoter regions (Fig S2B). In addition, adenovirus 
E1A protein has been shown to bind with p300 protein to inhibit the transcription of 
MGMT, leading to silencing of the MGMT promoter(Alonso et al., 2007). 
Retinoblastoma binding protein 4 (RBBP4) is a component of several chromatin 
modifying protein complexes evoking varying effects on gene expression, RBBP4 
interacts with CBP/ p300 to form a complex that drives the expression of MGMT. 
Moreover, it has been reported that RBBP4 is a negative modulator of TMZ sensitivity 
and that disruption of this protein enhances TMZ sensitivity through down-regulation 
of MGMT(Kitange et al., 2016). We explored whether RBBP4 expression was altered 
by PMX 465 (50 μM) treatment (48 h) in HCT116 cells (Fig S3). However, the 
expression of RBBP4 was not changed after treatment with PMX 465.  
In summary, we found that TMZ analog PMX 465 could down-regulate the 
expression of MGMT in HCT116 cells at the protein and mRNA levels. As shown in 
Fig.7, PMX 465 could reduce MGMT expression by increasing the binding of wild-
type p53 to the MGMT promoter and reducing the binding of Sp1 to the MGMT 
promoter. Experiments performed in p53 null cells, or cells possessing mutant p53 
demonstrated that the effects of PMX 465 on MGMT expression were dependent upon 
wt p53. Indeed, other DNA damaging chemotherapeutic agents may also down-regulate 
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MGMT expression in HCT116 cells via a wt p53-dependent manner. 
In conclusion, the mechanism of action of MGMT down-regulation by PMX 465 
in human colorectal carcinoma HCT116 cells was associated with increased binding of 
wt p53 with the MGMT promoter and disruption of Sp1 binding to the MGMT promoter.  
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